Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a large drop in short interest in February. As of February 15th, there was short interest totalling 1,390,000 shares, a drop of 93.1% from the January 31st total of 20,140,000 shares. Based on an average daily volume of 72,300 shares, the days-to-cover ratio is currently 19.2 days. Approximately 17.9% of the shares of the stock are short sold.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of KPTI. Velan Capital Investment Management LP bought a new position in shares of Karyopharm Therapeutics during the 4th quarter worth about $27,000. Focus Partners Wealth acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $31,000. TD Waterhouse Canada Inc. bought a new position in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $32,000. Two Sigma Advisers LP boosted its stake in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after buying an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP acquired a new position in Karyopharm Therapeutics during the fourth quarter worth $85,000. 66.44% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. HC Wainwright increased their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler boosted their price objective on Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Karyopharm Therapeutics has an average rating of “Moderate Buy” and an average price target of $62.75.

Karyopharm Therapeutics Trading Down 15.1 %

KPTI traded down $1.48 during midday trading on Thursday, reaching $8.35. The company’s stock had a trading volume of 209,739 shares, compared to its average volume of 77,273. The company has a fifty day simple moving average of $0.84 and a 200 day simple moving average of $0.82. The stock has a market cap of $1.05 billion, a P/E ratio of -8.19 and a beta of 0.06. Karyopharm Therapeutics has a twelve month low of $7.61 and a twelve month high of $25.50.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million. Sell-side analysts expect that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).